Medicure Inc. (MCUJF) Stock

About Medicure Inc.

Medicure Inc. operates as a biopharmaceutical company dedicated to the research, development, and commercialization of therapeutic solutions for the cardiovascular market, primarily serving Canada and the United States. Among its key offerings is AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist specifically designed to manage acute coronary syndrome, encompassing conditions like unstable angina and non-Q-wave myocardial infarction. The company also distributes ZYPITAMAG, a medication aimed at treating patients suffering from primary hyperlipidemia or mixed dyslipidemia. Additionally, Medicure provides ReDS, an innovative non-invasive medical device that facilitates the measurement of lung fluid, aiding in the effective management of congestive heart failure. Furthermore, its portfolio includes Sodium Nitroprusside injection, utilized for multiple critical applications: reducing elevated blood pressure during hypertensive crises in both adult and pediatric patients, inducing controlled hypotension to minimize surgical bleeding, and addressing acute congestive heart failure. These products are made available to consumers through both traditional retail pharmacies and online channels. Established in 1997, the company maintains its corporate headquarters in Winnipeg, Canada.

Medicure Inc. is headquartered in CA.

Medicure Inc. (MCUJF) stock trades at $0.67 with a market capitalization of $7.04M. The stock is valued at a price-to-earnings (P/E) ratio of -1.61, price-to-book of 0.86, price-to-sales of 0.35. Over the past 52 weeks the stock has ranged between $0.67 and $0.97, and currently trades 30.9% below its 52-week high.

On profitability, Medicure Inc. generates a return on equity (ROE) of -44.51%, return on capital employed of -50.71%, an operating margin of -21.07%, a net profit margin of -21.74%.

Official website: www.medicure.com